BB Biotech’s investment level decreased in Q4 (103.8% vs 115% limit), with divestments in top holdings as well as exits in five minor portfolio companies. BB Biotech’s is trading at a NAV discount of 11.4% versus its five-year average premium of 9.4%.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.